Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

Bacterial vaginosis is a prevalent condition characterized by an imbalance in the normal bacterial flora of the vagina, leading to symptoms such as unusual discharge, odor, and irritation. It is recognized as the most common cause of vaginitis, which can result in significant health complications if left untreated. These complications include pelvic inflammatory disease, an increased susceptibility to sexually transmitted diseases (STDs), and adverse reproductive outcomes, such as spontaneous abortion and preterm delivery. The procedure associated with CPT® Code 81513 involves a quantitative real-time amplification test that utilizes vaginal fluid specimens to detect specific RNA markers associated with the bacteria Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species. This test employs a technique known as transcription-mediated amplification (TMA), which is an isothermal amplification method that operates at a constant temperature, eliminating the need for thermal cycling. TMA utilizes two enzymes—RNA polymerase and reverse transcriptase—to facilitate the amplification of RNA, resulting in a billion-fold increase in RNA quantity within a short time frame, typically within one hour. The test can also incorporate a chemiluminescent target-specific probe, allowing for real-time molecular detection of the pathogens without the need for washing steps or transferring samples from one tube to another. This efficient process enables the simultaneous detection of multiple pathogenic organisms, and the results are interpreted using a proprietary algorithm that provides a straightforward positive or negative result for bacterial vaginosis.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The procedure associated with CPT® Code 81513 is indicated for the diagnosis of bacterial vaginosis, which is a common condition that can lead to various health complications. The following conditions and symptoms warrant the use of this test:

  • Bacterial Vaginosis Diagnosis The test is performed to confirm the presence of bacterial vaginosis in patients exhibiting symptoms such as abnormal vaginal discharge, odor, and irritation.
  • Risk Assessment for Complications It is indicated for patients at risk of developing pelvic inflammatory disease, STDs, or adverse reproductive outcomes, including spontaneous abortion and preterm delivery.

2. Procedure

The procedure for CPT® Code 81513 involves several key steps to ensure accurate detection of bacterial vaginosis through the analysis of vaginal fluid specimens. The following procedural steps are outlined:

  • Specimen Collection A sample of vaginal fluid is collected from the patient, ensuring that the specimen is obtained in a manner that minimizes contamination and preserves the integrity of the sample for testing.
  • Nucleic Acid Amplification The collected vaginal fluid is subjected to transcription-mediated amplification (TMA), which is an isothermal amplification technique. This process utilizes two enzymes, RNA polymerase and reverse transcriptase, to amplify the RNA markers specific to Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species.
  • Real-Time Detection The amplified RNA is then analyzed using a chemiluminescent target-specific probe, allowing for real-time detection of the amplified targets. This step is performed without the need for washing steps or transferring the sample to different tubes, which enhances the efficiency of the testing process.
  • Result Interpretation A proprietary algorithm processes the data obtained from the amplification and detection phases, converting the quantified RNA targets into a simple positive or negative result for bacterial vaginosis. This result provides clinicians with essential information for diagnosis and treatment planning.

3. Post-Procedure

After the completion of the procedure associated with CPT® Code 81513, the patient may not require any specific post-procedure care, as the test is non-invasive and involves only the collection of a vaginal fluid sample. However, it is essential for healthcare providers to communicate the results to the patient promptly. If the result is positive for bacterial vaginosis, appropriate treatment options should be discussed, which may include antibiotics or other therapeutic measures. Additionally, patients should be advised on the importance of follow-up care and monitoring for any recurrent symptoms or complications related to bacterial vaginosis.

Short Descr NFCT DS BV RNA VAG FLU ALG
Medium Descr NFCT DS BACTERAL VAGINOSIS RNA VAGINAL-FLUID ALG
Long Descr Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) none
MUE 1
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
AQ Physician providing a service in an unlisted health professional shortage area (hpsa)
GA Waiver of liability statement issued as required by payer policy, individual case
GV Attending physician not employed or paid under arrangement by the patient's hospice provider
GW Service not related to the hospice patient's terminal condition
GZ Item or service expected to be denied as not reasonable and necessary
KX Requirements specified in the medical policy have been met
SA Nurse practitioner rendering service in collaboration with a physician
XS Separate structure, a service that is distinct because it was performed on a separate organ/structure
Date
Action
Notes
2021-01-01 Added Code added.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"